Medtide Profits Surge as Peptide Capacity and Global Certifications Expand

Medtide, Inc. Class H ( (HK:3880) ) has provided an update.

Medtide Inc. reported strong results for 2025, with revenue rising 28.9% to RMB570.1 million and profit for the year surging 267.3% to RMB217.4 million, lifting net profit margin to 38.1%. During the year the company also completed a global offering and achieved a Hong Kong listing, underscoring its expansion ambitions and improved access to capital markets.

The group accelerated capacity expansion at its Qiantang site by installing new large-scale peptide production lines, lifting commercial-scale API capacity to well over one metric ton and per-batch capacity to more than 50 kilograms. It also secured key quality and regulatory milestones, including ISO 22716 certification, Chinese approvals for Goserelin Acetate and linaclotide APIs, and U.S. FDA green list status for semaglutide API, while growing its workforce 11% to support rising global demand for TIDES CRDMO services.

The most recent analyst rating on (HK:3880) stock is a Hold with a HK$38.00 price target. To see the full list of analyst forecasts on Medtide, Inc. Class H stock, see the HK:3880 Stock Forecast page.

More about Medtide, Inc. Class H

Medtide Inc. is a China-based joint stock company operating in the global peptide drug industry, providing integrated contract research, development and manufacturing (CRDMO) services for peptides and oligonucleotides. The group offers end-to-end solutions from drug discovery through commercial manufacturing, regulatory submission and approvals, serving long-term customers in more than 50 countries and regions with a growing focus on TIDES therapeutics including GLP-1 peptide programs.

Average Trading Volume: 121,245

Technical Sentiment Signal: Strong Sell

Current Market Cap: HK$3.18B

Find detailed analytics on 3880 stock on TipRanks’ Stock Analysis page.